Study of the effects of the implantable contraceptive Norplant® on lipid and lipoprotein metabolism

Contraception

Volumn 59, Issue 1, 1999, Pages 31-45

  Dusitsin, N ^a   Virutamasen, P ^a   Kaosaard, P ^a   Wongwathanavikrom, R ^a   Koetsawang, S ^a   Piya Anant, M ^a   Affandi, B ^a   Suherman, S K ^a   Cravioto, M C ^a   Valles, V ^a   Durand, M ^a   Gonzales, L ^a   Perez Palacios, G ^a   Ratnam, S S ^a   Singh, K ^a   Liew, D ^a   Landgren B , M ^a   Aedo, A R ^a   D'Arcangues, C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Levonorgestrel; Lipid metabolism; Norplant implants

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CONTRACEPTION; DRUG EFFECT; FEMALE; HUMAN; IMPLANTATION; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OUTCOMES RESEARCH; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; APOLIPOPROTEINS; CHOLESTEROL; CONFIDENCE INTERVALS; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; INDONESIA; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; LONGITUDINAL STUDIES; MEXICO; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SINGAPORE; SWEDEN; THAILAND; TRIGLYCERIDES;

EID: 0032966106     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00149-8     Document Type: Article

References (24)

1. Lithell H., Weiner E., Vessby B., et al. Effects of continuous levonorgestrel treatment (subcutaneous capsules) on the lipoprotein and carbohydrate metabolism in fertile women. Uppsala J Med Sci. 88:1983;103-108.
2. Roy S., Mishell D.R. Jr, Robertson D.N., et al. Long-term reversible contraception with levonorgestrel-releasing Silastic rods. Am J Obstet Gynecol. 148:1984;1006-1013.
3. Holma P., Robertson D.N. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel. Contraception. 32:1985;163-171.
4. Otubu J.A.M., Towobola O.A., Aisien A.O., et al. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins. Contraception. 47:1993;149-159.
5. Noerpramana N.P. Blood lipid fractions the side-effects and continuation of Norplant use . Adv Contracept. 13:1997;13-37.
6. Croxatto H.B., Diaz S., Robertson D.N., et al. Clinical chemistry in women treated with levonorgestrel implants. Contraception. 27:1983;281-288.
7. Affandi B., Suherman S.K., Prihartono D.J., et al. Serum lipids in Norplant implant users a cross-sectional study . Contraception. 36:1987;429-434.
8. Shaaban M.M., Elwan S.I., Abdalla S.A., et al. Effect of subdermal levonorgestrel contraceptive implants, Norplant, on serum lipids. Contraception. 30:1984;413-419.
9. Singh K., Viegas O.A.C., Loke D.F.M., et al. Evaluation of liver function and lipid metabolism following Norplant implant removal. Adv Contracept. 9:1993;41-47.
10. Allain C.C., Poon L.S., Chan C.S.G. Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470-475.
11. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 19:1973;476-482.
12. Grove T.H. Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate/magnesium. Clin Chem. 25:1979;560-564.
13. Assmann G., Jabs H.U., Kohnert U., et al. LDL-cholesterol determination in blood following precipitation of LDL with polyvinyl sulfate. Clin Chim Acta. 140:1984;77-83.
14. Siedel J., Schiefer S., Rosseneu M., et al. Immunoturbidimetric method for routine determinations of apolipoproteins AI, AII and B in normo- and hyperlipemic sera comparative evaluation against immunonephelometry . Clin Chem. 34:1988;1821-1825.
15. Castelli W.P., Anderson K., Wilson P.W., Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 2:1992;23-28.
16. Uccella R., Donnini P., Franzetti I., Gaiazzi M. Serum lipid pattern as severity indicator of angiographically assessed coronary artery disease. Artery. 20:1993;346-360.
17. La Rosa JC. Dyslipoproteinemia in women and the elderly. Med Clin North Am. 78:1994;163-180.
18. Kannel W.B. Metabolic risk factors for coronary heart disease in women perspective from the Framingham Study . Am Heart J. 114:1987;413-419.
19. Brunner D., Weisbort J., Meshulam N., et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events twenty-year follow-up of the Donodo-Tel Aviv Prospective Coronary Artery Disease Study . Am J Cardiol. 59:1987;1271-1276.
20. Jacobs D.R., Mebane I.L., Bangdiwala S.I., et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women the follow-up study of the Lipid Research Clinics' Prevalence Study . Am J Epidemiol. 131:1990;32-47.
21. Kostner G.M. Apolipoproteins and lipoproteins of human plasma significance in health and in disease . Adv Lipid Res. 20:1983;1-43.
22. Fraser I.S., Tiitinen A., Affandi B., et al. Norplant consensus statement and background review. Contraception. 57:1998;1-9.
23. World Health Organization. Cardiovascular disease and steroid hormone contraception. WHO Technical Report Series (No. 877), 1997:89.
24. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives results of an international multicenter case-control study . Contraception. 57:1998;315-324.